Compare Abeona Therapeutics Inc (ABEO) vs Dell Technologies Inc (DELL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Dell Technologies Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Dell Technologies Inc trades at $429.59 (market cap $269.62B). The key difference: Dell Technologies Inc is far larger — about 722.2× Abeona Therapeutics Inc's market cap, and Dell Technologies Inc pays a 0.6% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DELL | |
|---|---|---|
Market Cap | $373.32M | $269.62B |
Sector | Health | Technology |
52-Week High | $7.23 | $466.02 |
52-Week Low | $4.17 | $111.10 |
Enterprise Value | $228.22M | $289.21B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Dell Technologies trades at $416.98, up 5.75% in the last 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $484.28. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $4.86 surpassing the $2.96 estimate. The company shows strong revenue growth projections to $134 billion in 2026 and benefits from AI server demand, though net cash flow was negative $3.69 billion in 2025.
The outlook for Dell is positive, driven by AI infrastructure dominance and expanding profit margins, but risks include supply constraints, competitive pressures, and negative shareholder equity. With 57.8% of analysts rating it a buy, the stock offers growth potential, yet investors should weigh execution risks against the robust AI-driven revenue backlog.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →
